Viralytics Limited (ASX:VLA) is heading to market with a capital raising.
The ASX has granted the company a trading halt, with its shares placed in pre-open.
Earlier in the week Viralytics received $2.9 million from the Australian Taxation Office as a R&D claim for FY15.
Viralytics is focussed on the area of developing oncolytic immunotherapy treatments for a range of cancers.
The halt will last until the opening of trade on Monday 14th December 2015, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.